Valuation: Guided Therapeutics, Inc.

Market Cap 9.65M 8.79M 8.1M 7.37M 13.83M 894M 14.53M 98.61M 39.19M 488M 36.22M 35.46M 1.53B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 12.53M 11.41M 10.52M 9.57M 17.94M 1.16B 18.86M 128M 50.87M 634M 47.01M 46.02M 1.99B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
62.42%
Yield 2024 *
-
Yield 2025 -
1 week+108.18%
Current month+52.67%
1 month+20.53%
3 months-15.19%
6 months+18.47%
Current year-57.59%
1 week 0.1
Extreme 0.1
0.23
1 month 0.1
Extreme 0.1
0.23
Current year 0.1
Extreme 0.1
0.54
1 year 0.1
Extreme 0.1
0.54
3 years 0.06
Extreme 0.064
0.54
5 years 0.06
Extreme 0.062
0.78
10 years 0.02
Extreme 0.0206
1,700
Manager TitleAgeSince
Chief Executive Officer 70 05/03/2023
Chief Tech/Sci/R&D Officer 70 01/12/2010
Director TitleAgeSince
Director/Board Member 76 09/04/2006
Director/Board Member 69 09/11/2016
Director/Board Member 70 30/11/2016
Date Insider Type Main position Quantity % Market Cap. Importance
10/03/26 Free

Chairman

110,000 0.1316%
10/03/26 Others

Director

466,991 0.5586%
10/03/26 Free

Director

110,000 0.1316%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+108.18%-8.40%+81.75% 9.65M
-2.79%-4.38%+16.90%+42.75% 248B
-3.16%-5.43%-0.82%+4.42% 155B
-2.01%-10.04%-27.74%+28.17% 138B
-2.35%-5.32%-56.54%-22.92% 60.85B
-1.95%-4.95%+21.12%+51.59% 58.56B
-1.96%-2.25%+4.04%-14.08% 52.46B
-2.83%-2.06%+17.45%+49.48% 48.04B
-3.51%-4.30%+16.33%+68.80% 43.29B
+1.26%-11.71%-1.58%+48.97% 43.1B
Average -1.93%-3.79%-1.92%+33.89% 85B
Weighted average by Cap. -2.42%-3.87%-0.34%+27.77%

Financials

2024 2025
Net sales 7K 6.38K 5.87K 5.34K 10.03K 648K 10.54K 71.5K 28.42K 354K 26.26K 25.71K 1.11M 767K 699K 644K 586K 1.1M 71.02M 1.15M 7.83M 3.11M 38.79M 2.88M 2.82M 122M
Net income -2.42M -2.2M -2.03M -1.85M -3.46M -224M -3.64M -24.69M -9.81M -122M -9.07M -8.88M -384M -3.2M -2.91M -2.68M -2.44M -4.58M -296M -4.81M -32.65M -12.97M -162M -11.99M -11.74M -507M
Net Debt 1.77M 1.61M 1.49M 1.35M 2.54M 164M 2.67M 18.09M 7.19M 89.57M 6.64M 6.5M 281M 2.88M 2.62M 2.41M 2.2M 4.12M 266M 4.33M 29.38M 11.68M 145M 10.79M 10.56M 457M
Projected Income Statement - Annual - Guided Therapeutics, Inc.
Logo Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
3
Date Price Change Volume
20/11/26 US$0.1000 -1.19% 11,300
19/11/26 US$0.1012 -8.00% 15,401
18/11/26 US$0.1100 +7.84% 8,345
17/11/26 US$0.1020 -7.27% 34,001
16/11/26 US$0.1100 -.--% 3,200
  1. Stock Market
  2. Stocks
  3. GTHP Stock